Cardiovascular Disease

As the leading cause of death worldwide, cardiovascular disease is one of the most debilitating and well-recognized manifestations of cardiometabolic decline. Coronary artery disease, heart failure, peripheral artery disease, and arrhythmia are just some cardiovascular diseases that lead to lower quality of life, increased mortality, and significant health care costs.

CME Activities

Available courses, certification information, and the latest educational opportunities for practitioners interested in beginning or continuing their careers in a cardiometabolic subspecialty with emphasis on cardiovascular disease.

News Digest

The latest industry news, CMHC Pulse Blogs and Cardiometabolic Chronicle articles related to cardiovascular disease.

Association of Depression and Poor Mental Health With Cardiometabolic Disease in Women 

Dive into the intersection of mental health and cardiometabolic disease in women.

Remembering Dr. Stephen Harrison 

Cardiometabolic Health Congress is saddened to learn that faculty Col. Stephen A. Harrison, MD, FAASLD, passed away on April 23.

FDA Extends Approval for Alirocumab to Lower LDL-C in Pediatric Patients with HeFH 

FDA Expands Labels for Bempedoic Acid Tablets and Combination Bempedoic Acid and Ezetimibe Tablets to Reduce Cardiovascular Risk 

Cardiometabolic Health Congress Hosts the 2024 Women’s Masterclass in California to Advance Cardio-renal-metabolic Care for Women  

How To Overcome Clinical Disparities in Women with Chronic Kidney Disease (CKD)

5 Keys to Patient Education on GLP-1 RAs for Weight Loss

Championing Change: Celebrating Cardiometabolic Health Congress (CMHC) Women Faculty

Comprehensive Overview of GLP-1 RAs in Cardiometabolic Care








Cardiovascular Disease

Colchicine is an anti-inflammatory drug derived from Colchicum autumnale, a toxic autumn-blooming flowering plant commonly known as autumn crocus or meadow saffron. The alkaloid is


Cardiovascular Disease

In honor of World Sleep Day 2023, we sat down with Cardiometabolic Health Congress (CMHC) faculty member Lee A. Surkin, MD, founder of the American


Cardiovascular Disease

Investigators reported that baxdrostat – at several dose levels – reduced plasma aldosterone levels but not cortisol levels in results from the recent BrigHTN study


Cardiometabolic Disease

The experts at Cardiometabolic Health Congress (CMHC) have selected the TOP 10 developments, approvals, news, and findings from 2022 that impact the field of cardiorenal



Hundreds of practitioners gathered at the Boston Park Plaza for the annual conference from Cardiometabolic Health Congress (CMHC) on Oct. 19-22, 2022. Founded in 2006,


Cardiometabolic Disease

Hundreds of practitioners gathered today at the Boston Park Plaza for the annual conference from Cardiometabolic Health Congress (CMHC). In the past 17 years, this

Expert Highlights and Perspectives

A cache of recorded faculty presentations addressing the diagnosis, clinical management, treatment, and emerging strategies related to cardiovascular disease.

Iron Deficiency in Heart Failure: An Overview (recorded July 2022)​

Javed Butler, MD, MPH, MBA

Screening and Diagnosis of Iron Deficiency in Heart Failure (recorded July 2022)

Javed Butler, MD, MPH, MBA

Treatment of Iron Deficiency: Clinical Trials & Evidence (recorded July 2022)

Javed Butler, MD, MPH, MBA

Expert Discussions: The Role of IV Iron in Patients with HF (recorded July 2022)

Javed Butler, MD, MPH, MBA

Challenging Cases in Patients with Iron Deficiency and Heart Failure (recorded July 2022)

Javed Butler, MD, MPH, MBA

A Call to Action: Women and Peripheral Artery Disease

Roxana Mehran, MD, Professor of Medicine at Mount Sinai and an internationally-recognized expert, covers the current disparities in the underdiagnosis and undertreatment of peripheral artery disease (PAD) in women, as well as advances and clinical pearls to improve the care of women with PAD (recorded August 2023).

Primary and Secondary Cardiovascular Prevention: Essential or Too Simplistic?

Watch as CMHC Chair Christie M. Ballantyne, MD moderates an engaging interview with Pam R. Taub, MD, and Salim S. Virani, MD, PhD, recapping a debate at 2022 CMHC Spring titled “Drawing the Line Between Primary and Secondary Cardiovascular Prevention: Essential or Too Simplistic?” (recorded April 2022).

Diabetes and the Increase Risk of Atherothrombotic Events


  • Increased platelet aggregation & activation in diabetes patients
  • Reduced responsiveness to commonly-used antiplatelet agents
  • The role of antiplatelet therapy in patients with diabetes
  • Summary and contextualization of THEMIS & THEMIS-PCI trials

How Do These Advances Fit in With Existing Therapies and Other Updates in Secondary Prevention in Diabetes Patients?


  • Going beyond glucose in diabetes
  • Multifactorial risk reduction
  • SGLT-2 inhibitors & recent updates

Advances in Dual Pathway Inhibition in Diabetes Patients


  • Overlap between dual antiplatelet therapy (DAPT) and dual pathway inhibition (DPI)
  • Which form of double antithrombotic agent/regimen should be used in patient
  • Integrating and interpreting the data from COMPASS and THEMIS/THEMIS-PCI

The Screening, Diagnosis, and Medical Treatment of PAD: A Detailed Overview

Watch as our faculty and PAD experts Marc Bonaca, MD and Sonia Anand, MD, cover in detail the screening, diagnosis, and medical management of PAD, as part of our Interventional Cardiology Masterclass

(recorded January 29, 2022).

Watch Drs. Bhatt, Bonaca, and Patel recap the symposium at 2021 CMHC Spring, as well as discuss some recent data on antithrombotic therapy for PAD that were presented at 2021 American College of Cardiology meeting, including:

  • The concept and the rationale of total (first and subsequent) events in PAD
  • Total vascular events in the VOYAGER-PAD trial: efficacy and safety
  • Implications of these recent sub-analyses
  • Dual antiplatelet therapy (DAPT) vs. dual platelet inhibition (DPI):
    patient selection and strategies

Watch as experts Deepak Bhatt, MD, Marc Bonaca, MD, and Manesh Patel, MD, discuss additional clinical pearls from the 2020 CMHC Annual Meeting on the management of high-risk peripheral artery disease patients, including:

  • Summary of the main results of the COMPASS and VOYAGER-PAD trials
  • Summary of sub-analyses of these trials
  • Take home points and practice implications

CMHC | Bonaca ESC 2021 Interview

Marc Bonaca,

Marc Bonaca, MD, one of the principal investigators of the VOYAGER-PAD trial, join us to discuss new data presented at the 2021 European Society of Cardiology.

CMHC | Bonaca Interview

Marc Bonaca,

Marc Bonaca, MD, one of the principal investigators of the VOYAGER-PAD trial, join us to discuss new data presented at the 2021 European Society of Cardiology.

Patient Story: Considering Iron Deficiency in Heart Failure

Andy Y. Lee

Heart Failure Cardiologist Assistant Clinical Professor University of California Irvine, School of Medicine

Andy Y. Lee, MD, heart failure cardiologist and Assistant Clinical Professor at University of California Irvine School of Medicine, shares his story about a HF patient with ID.

Iron Deficiency in Heart Failure with Dr. Bozkurt

Biykem Bozkurt

Professor of Medicine Associate Provost of Faculty Affairs, Senior Associate Dean of Faculty Development Director, Winters Center for Heart Failure Research Assoc. Director, Cardiovascular Research Institute Baylor College of Medicine Immediate Past President of the HFSA Houston, TX

Interventional Cardiology


A collection of resources related to cardiovascular disease for both patients and provider education and connection.
Quick Links

Other Resources

Peer To Peer Toolkit
Preventing Cardiovascular Events in High-Risk Diabetes Patients with CAD: New Insights and Developments

Peer To Peer Toolkit

A compilation of key content from the Primetime Symposium at the 2020 15th Annual CMHC Live Online
A compilation of key content from the Primetime Symposium at 2021 CMHC Spring
Dual Pathway Inhibition: Mechanistic Rationale for Atherothrombotic Risk Reduction
Clinical Brief
The Disproportionate Burden of ATTR-CM In African Americans

Drug Pipeline

Key emerging approaches across the spectrum of cardiovascular disease that are being studied in various stages of clinical trials, or that were recently approved by the U.S. Food and Drug Administration for therapeutic use.

Heart Failure



Peripheral Artery Disease (PAD)



Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.